Davies R J, Nelson H S
Department of Respiratory Medicine and Allergy, Royal London Hospital, United Kingdom.
Clin Ther. 1997 Jan-Feb;19(1):27-38; discussion 2-3. doi: 10.1016/s0149-2918(97)80070-7.
Once-daily mometasone furoate nasal spray (MFNS) is a new intranasal glucocorticoid for the treatment of seasonal allergic rhinitis and perennial rhinitis, and for the prophylaxis of seasonal allergic rhinitis. This paper reviews key findings from the clinical development program for MFNS, comprising more than 20 clinical trials with more than 6000 patients worldwide. MFNS exhibits strong anti-inflammatory activity in vitro and in vivo, and has a rapid onset of action, affording clinically significant symptom relief in 28% of patients within 12 hours of the first dose. Once-daily MFNS is at least as effective as other intranasal glucocorticoids, including twice-daily beclomethasone dipropionate and once-daily fluticasone propionate and budesonide. MFNS is well tolerated and has no detectable effect on the hypothalamic-pituitary-adrenal axis, even at up to 20 times the recommended daily dose. MFNS does not cause atrophy of the nasal mucosa; in fact, prolonged treatment tends to restore the nasal mucosa to a more normal phenotype. The once-daily dosing schedule of MFNS may improve patient compliance, while its high margin of systemic safety and rapid onset of action may enhance patient and physician acceptance.
糠酸莫米松鼻喷雾剂（MFNS）每日一次，是一种新型鼻内用糖皮质激素，用于治疗季节性变应性鼻炎和常年性鼻炎，以及预防季节性变应性鼻炎。本文回顾了MFNS临床研发项目的主要研究结果，该项目包括全球范围内针对6000多名患者开展的20多项临床试验。MFNS在体外和体内均表现出强大的抗炎活性，起效迅速，在首次给药后12小时内即可使28%的患者临床症状得到显著缓解。每日一次的MFNS至少与其他鼻内用糖皮质激素同样有效，包括每日两次的二丙酸倍氯米松以及每日一次的丙酸氟替卡松和布地奈德。MFNS耐受性良好，即使剂量高达推荐日剂量的20倍，对下丘脑-垂体-肾上腺轴也无明显影响。MFNS不会导致鼻黏膜萎缩；事实上，长期治疗往往会使鼻黏膜恢复到更正常的表型。MFNS每日一次的给药方案可能会提高患者的依从性，而其较高的全身安全性和快速起效可能会提高患者和医生的接受度。
